Analysis of liver metastasis in colorectal cancer
Integrative Analysis of CRC Liver Metastasis
This study is looking at the differences in proteins between normal colorectal tissue and colorectal cancer tissue with and without liver metastasis to see how these changes might help understand the disease better.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 1000 (estimated) |
| Ages | 18 Years to 75 Years |
| Sex | All |
| Sponsor | Shanghai 10th People's Hospital Academic / other |
| Drugs / interventions | chemotherapy |
| Locations | 2 sites (Ganzhou, Jiangxi and 1 other locations) |
| Trial ID | NCT02917707 on ClinicalTrials.gov |
What this trial studies
This study focuses on the integrative analysis of liver metastasis in colorectal cancer (CRC) by examining the proteomes of paired normal colorectal tissues and CRC tissues with or without liver metastasis. The methodology includes sequencing transcriptomes, whole exome sequencing, and single nucleotide polymorphism (SNP) array profiling for triplets of normal colorectal tissue, primary CRC, and its matched liver metastasis. Additionally, the study will analyze genomic data from CRC previously characterized by The Cancer Genome Atlas (TCGA) to conduct comprehensive proteogenomic analyses.
Who should consider this trial
Good fit: Ideal candidates for this study are patients aged 75 years or younger with histologically confirmed colorectal cancer and a WHO performance status of 0 or 1.
Not a fit: Patients over 75 years old, those with severe organ dysfunction, or those who have received prior cancer chemotherapy may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could enhance the understanding of CRC liver metastasis, potentially leading to improved treatment strategies.
How similar studies have performed: Other studies have shown success in analyzing CRC and its metastasis, but this specific integrative approach is relatively novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Age ≤ 75 years with histologically proven CRC * No severe major organ dysfunction * WHO performance status of 0 or 1 * No prior cancer chemotherapy Exclusion Criteria: * Age ≥ 76 * Severe major organ dysfunction * World Health Organization (WHO) performance status of \>1 * Prior cancer chemotherapy
Where this trial is running
Ganzhou, Jiangxi and 1 other locations
- Ganzhou City People's Hospital — Ganzhou, Jiangxi, China (Recruiting)
- Shanghai Tenth People's Hospital — Shanghai, Shanghai Municipality, China (Recruiting)
Study contacts
- Principal investigator: Da Fu, Ph.D. — the Shanghai Tenth People's Hospital
- Study coordinator: Da Fu, Ph.D.
- Email: shsyiec@126.com
- Phone: 021-66301604
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.